Roche scraps skyscraper HQ, to develop alternative project
Roche had originally intended to submit its building application for the high-rise in the second quarter of 2009. However, in the course of the development work it became
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.